What was the overall market valuation of the US hepatitis c-drugs market in 2024?

The overall market valuation was $3750.0 Million in 2024. Read More

What is the projected market valuation for the US hepatitis c-drugs market by 2035?

The projected valuation for 2035 is $5100.0 Million. Read More

What is the expected CAGR for the US hepatitis c-drugs market during the forecast period 2025 - 2035?

The expected CAGR for the market during the forecast period 2025 - 2035 is 2.83%. Read More

Which companies are considered key players in the US hepatitis c-drugs market?

Key players include Gilead Sciences, AbbVie, Merck & Co, Bristol-Myers Squibb, Johnson & Johnson, Roche, Novartis, Mylan, and the Hepatitis C Foundation. Read More

What segment had the highest valuation in the US hepatitis c-drugs market in 2024?

The Direct Acting Antivirals segment had the highest valuation at $2250.0 Million in 2024. Read More

How does the valuation of Combination Therapies compare to Ribavirin in 2024?

In 2024, Combination Therapies were valued at $250.0 Million, whereas Ribavirin was valued at $500.0 Million. Read More

What is the valuation range for Oral administration route in the US hepatitis c-drugs market?

The valuation range for the Oral administration route is between $1500.0 Million and $2100.0 Million. Read More

What was the market valuation for Experienced Patients in 2024?

The market valuation for Experienced Patients was between $2000.0 Million and $2700.0 Million in 2024. Read More

What is the projected growth trend for Long-Term treatment duration from 2025 to 2035?

The Long-Term treatment duration segment is expected to grow from $2500.0 Million to $3500.0 Million from 2025 to 2035. Read More

What is the valuation range for Injectable administration route in 2024?

The valuation range for the Injectable administration route was between $1200.0 Million and $1600.0 Million in 2024. Read More

US Hepatitis C Drugs Market

United States Hepatitis C Drugs Market Research Report: Size, Share, Trend Analysis By Types (Direct Acting Antivirals, Interferon-Based Therapies, Ribavirin, Combination Therapies) By Patient Type (Naive Patients, Experienced Patients, Special Population) By Treatment Duration (Short-Term, Long-Term, Preventive Treatment) By Administration (Route Oral, Injectable, Intranasal) - Growth Outlook & Industry Forecast 2025 To 2035

Forecast Period

2025 - 2035

CAGR

2.83%

2024 Market Size

$ 3,750 Million

2035 Market Size

$ 5,100 Million

Pharmaceutical ● Updated April 2026 Report ID: MRFR/Pharma/16426-HCR | Pages: 100 | Author: Satyendra Maurya, Garvit Vyas

Summary Table of Contents Segmentation Download PDF

1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
1. 1.1 EXECUTIVE SUMMARY
  1. 1.1.1 Market Overview
  2. 1.1.2 Key Findings
  3. 1.1.3 Market Segmentation
  4. 1.1.4 Competitive Landscape
  5. 1.1.5 Challenges and Opportunities
  6. 1.1.6 Future Outlook
2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
1. 2.1 MARKET INTRODUCTION
  1. 2.1.1 Definition
  2. 2.1.2 Scope of the study
    1. 2.1.2.1 Research Objective
    2. 2.1.2.2 Assumption
    3. 2.1.2.3 Limitations
2. 2.2 RESEARCH METHODOLOGY
  1. 2.2.1 Overview
  2. 2.2.2 Data Mining
  3. 2.2.3 Secondary Research
  4. 2.2.4 Primary Research
    1. 2.2.4.1 Primary Interviews and Information Gathering Process
    2. 2.2.4.2 Breakdown of Primary Respondents
  5. 2.2.5 Forecasting Model
  6. 2.2.6 Market Size Estimation
    1. 2.2.6.1 Bottom-Up Approach
    2. 2.2.6.2 Top-Down Approach
  7. 2.2.7 Data Triangulation
  8. 2.2.8 Validation
3 SECTION III: QUALITATIVE ANALYSIS
1. 3.1 MARKET DYNAMICS
  1. 3.1.1 Overview
  2. 3.1.2 Drivers
  3. 3.1.3 Restraints
  4. 3.1.4 Opportunities
2. 3.2 MARKET FACTOR ANALYSIS
  1. 3.2.1 Value chain Analysis
  2. 3.2.2 Porter's Five Forces Analysis
    1. 3.2.2.1 Bargaining Power of Suppliers
    2. 3.2.2.2 Bargaining Power of Buyers
    3. 3.2.2.3 Threat of New Entrants
    4. 3.2.2.4 Threat of Substitutes
    5. 3.2.2.5 Intensity of Rivalry
  3. 3.2.3 COVID-19 Impact Analysis
    1. 3.2.3.1 Market Impact Analysis
    2. 3.2.3.2 Regional Impact
    3. 3.2.3.3 Opportunity and Threat Analysis
4 SECTION IV: QUANTITATIVE ANALYSIS
1. 4.1 Medical Device, BY Type (USD Million)
  1. 4.1.1 Direct Acting Antivirals
  2. 4.1.2 Interferon-Based Therapies
  3. 4.1.3 Ribavirin
  4. 4.1.4 Combination Therapies
2. 4.2 Medical Device, BY Administration Route (USD Million)
  1. 4.2.1 Oral
  2. 4.2.2 Injectable
  3. 4.2.3 Intranasal
3. 4.3 Medical Device, BY Treatment Duration (USD Million)
  1. 4.3.1 Short-Term
  2. 4.3.2 Long-Term
  3. 4.3.3 Preventive Treatment
4. 4.4 Medical Device, BY Patient Type (USD Million)
  1. 4.4.1 Naive Patients
  2. 4.4.2 Experienced Patients
  3. 4.4.3 Special Population
5 SECTION V: COMPETITIVE ANALYSIS
1. 5.1 Competitive Landscape
  1. 5.1.1 Overview
  2. 5.1.2 Competitive Analysis
  3. 5.1.3 Market share Analysis
  4. 5.1.4 Major Growth Strategy in the Medical Device
  5. 5.1.5 Competitive Benchmarking
  6. 5.1.6 Leading Players in Terms of Number of Developments in the Medical Device
  7. 5.1.7 Key developments and growth strategies
    1. 5.1.7.1 New Product Launch/Service Deployment
    2. 5.1.7.2 Merger & Acquisitions
    3. 5.1.7.3 Joint Ventures
  8. 5.1.8 Major Players Financial Matrix
    1. 5.1.8.1 Sales and Operating Income
    2. 5.1.8.2 Major Players R&D Expenditure. 2023
2. 5.2 Company Profiles
  1. 5.2.1 Gilead Sciences (US)
    1. 5.2.1.1 Financial Overview
    2. 5.2.1.2 Products Offered
    3. 5.2.1.3 Key Developments
    4. 5.2.1.4 SWOT Analysis
    5. 5.2.1.5 Key Strategies
  2. 5.2.2 AbbVie (US)
    1. 5.2.2.1 Financial Overview
    2. 5.2.2.2 Products Offered
    3. 5.2.2.3 Key Developments
    4. 5.2.2.4 SWOT Analysis
    5. 5.2.2.5 Key Strategies
  3. 5.2.3 Merck & Co (US)
    1. 5.2.3.1 Financial Overview
    2. 5.2.3.2 Products Offered
    3. 5.2.3.3 Key Developments
    4. 5.2.3.4 SWOT Analysis
    5. 5.2.3.5 Key Strategies
  4. 5.2.4 Bristol-Myers Squibb (US)
    1. 5.2.4.1 Financial Overview
    2. 5.2.4.2 Products Offered
    3. 5.2.4.3 Key Developments
    4. 5.2.4.4 SWOT Analysis
    5. 5.2.4.5 Key Strategies
  5. 5.2.5 Johnson & Johnson (US)
    1. 5.2.5.1 Financial Overview
    2. 5.2.5.2 Products Offered
    3. 5.2.5.3 Key Developments
    4. 5.2.5.4 SWOT Analysis
    5. 5.2.5.5 Key Strategies
  6. 5.2.6 Roche (CH)
    1. 5.2.6.1 Financial Overview
    2. 5.2.6.2 Products Offered
    3. 5.2.6.3 Key Developments
    4. 5.2.6.4 SWOT Analysis
    5. 5.2.6.5 Key Strategies
  7. 5.2.7 Novartis (CH)
    1. 5.2.7.1 Financial Overview
    2. 5.2.7.2 Products Offered
    3. 5.2.7.3 Key Developments
    4. 5.2.7.4 SWOT Analysis
    5. 5.2.7.5 Key Strategies
  8. 5.2.8 Mylan (US)
    1. 5.2.8.1 Financial Overview
    2. 5.2.8.2 Products Offered
    3. 5.2.8.3 Key Developments
    4. 5.2.8.4 SWOT Analysis
    5. 5.2.8.5 Key Strategies
  9. 5.2.9 Hepatitis C Foundation (US)
    1. 5.2.9.1 Financial Overview
    2. 5.2.9.2 Products Offered
    3. 5.2.9.3 Key Developments
    4. 5.2.9.4 SWOT Analysis
    5. 5.2.9.5 Key Strategies
3. 5.3 Appendix
  1. 5.3.1 References
  2. 5.3.2 Related Reports
6 LIST OF FIGURES
1. 6.1 MARKET SYNOPSIS
2. 6.2 US MARKET ANALYSIS BY TYPE
3. 6.3 US MARKET ANALYSIS BY ADMINISTRATION ROUTE
4. 6.4 US MARKET ANALYSIS BY TREATMENT DURATION
5. 6.5 US MARKET ANALYSIS BY PATIENT TYPE
6. 6.6 KEY BUYING CRITERIA OF MEDICAL DEVICE
7. 6.7 RESEARCH PROCESS OF MRFR
8. 6.8 DRO ANALYSIS OF MEDICAL DEVICE
9. 6.9 DRIVERS IMPACT ANALYSIS: MEDICAL DEVICE
10. 6.10 RESTRAINTS IMPACT ANALYSIS: MEDICAL DEVICE
11. 6.11 SUPPLY / VALUE CHAIN: MEDICAL DEVICE
12. 6.12 MEDICAL DEVICE, BY TYPE, 2024 (% SHARE)
13. 6.13 MEDICAL DEVICE, BY TYPE, 2024 TO 2035 (USD Million)
14. 6.14 MEDICAL DEVICE, BY ADMINISTRATION ROUTE, 2024 (% SHARE)
15. 6.15 MEDICAL DEVICE, BY ADMINISTRATION ROUTE, 2024 TO 2035 (USD Million)
16. 6.16 MEDICAL DEVICE, BY TREATMENT DURATION, 2024 (% SHARE)
17. 6.17 MEDICAL DEVICE, BY TREATMENT DURATION, 2024 TO 2035 (USD Million)
18. 6.18 MEDICAL DEVICE, BY PATIENT TYPE, 2024 (% SHARE)
19. 6.19 MEDICAL DEVICE, BY PATIENT TYPE, 2024 TO 2035 (USD Million)
20. 6.20 BENCHMARKING OF MAJOR COMPETITORS
7 LIST OF TABLES
1. 7.1 LIST OF ASSUMPTIONS
7.1.1
1. 7.2 US MARKET SIZE ESTIMATES; FORECAST
  1. 7.2.1 BY TYPE, 2025-2035 (USD Million)
  2. 7.2.2 BY ADMINISTRATION ROUTE, 2025-2035 (USD Million)
  3. 7.2.3 BY TREATMENT DURATION, 2025-2035 (USD Million)
  4. 7.2.4 BY PATIENT TYPE, 2025-2035 (USD Million)
2. 7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
7.3.1
1. 7.4 ACQUISITION/PARTNERSHIP
7.4.1

Certified Researchers

Customize Report

US Hepatitis C Drugs Market Segmentation

US Hepatitis C Drugs Market By Type (USD Million, 2025-2035)

Direct Acting Antivirals
Interferon-Based Therapies
Ribavirin
Combination Therapies

US Hepatitis C Drugs Market By Administration Route (USD Million, 2025-2035)

Oral
Injectable
Intranasal

US Hepatitis C Drugs Market By Treatment Duration (USD Million, 2025-2035)

Short-Term
Long-Term
Preventive Treatment

US Hepatitis C Drugs Market By Patient Type (USD Million, 2025-2035)

Naive Patients
Experienced Patients
Special Population

Certified Researchers

Customize Report

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”

Rob Kooiker Group Product Manager HVAC & Fire Protection GMA

“We got the report in time, we really thank you for your support in this process. I also thank to all of your team as they did a great job.”

Akif Moroglu Strategy & Business Development Director

“The Automotive 48V ECU Components Procurement Intelligence Study” was a complex project, but the Market Research Future (MRFR) team handled it with quality, agility, and customer-centricity. They delivered all requested data on time and within the agreed scope. The team, including Shubhendra Anand and Rahul Gotadki, was always readily available to clarify questions and swiftly implement necessary adjustments, driving the project to a successful conclusion within a very demanding timeframe.
I would also like to specifically commend Akshay Agarwal for his responsiveness and support at every stage—from our initial inquiry on May 6th through to final delivery on June 18th. His dedication made the entire process seamless.”